Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Johnson & Johnson reçoit le marquage CE pour les lentilles de contact réutilisables ACUVUE OASYS MAX

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has announced that it received CE marking for its new reusable contact lens, ACUVUE OASYS MAX 2-Week. This lens features exclusive MAX technologies aimed at providing enhanced comfort and visual clarity, even on day 14 of use. The product is set to launch in select European countries later this year, with a broader rollout planned for 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • Johnson & Johnson received CE marking for ACUVUE OASYS MAX.
  • The lens offers superior comfort and visual clarity.
  • Deployment in European countries is planned for later this year.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Canagliflozin
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

LIMERICK, Irlande--(BUSINESS WIRE)--Johnson & Johnson (NYSE : JNJ) annonce aujourd'hui avoir reçu le marquage CE pour ACUVUE OASYS MAX 2-Week,*** une nouvelle lentille de contact réutilisable dotée de technologies MAX exclusives conçues pour offrir un confort et une clarté visuelle supérieurs, même au jour 14.*†i¥1 La lentille sera déployée dans certains pays européens plus tard cette année avec un déploiement plus large sur le marché en 2027. À l’échelle mondiale, 140 millions de personnes

Frequently Asked Questions

What is ACUVUE OASYS MAX?

ACUVUE OASYS MAX is a new reusable contact lens designed for superior comfort and clarity.

When will ACUVUE OASYS MAX be available?

The lens will be deployed in select European countries later this year.

What technologies does ACUVUE OASYS MAX use?

It features exclusive MAX technologies for enhanced comfort and visual clarity.

What is the global reach of ACUVUE OASYS MAX?

Globally, 140 million people are expected to benefit from this product.

ShareAdd on Google
Tags: JNJ Viatris Investor Conferences Healthcare Johnson & Johnson ACUVUE OASYS MAX CE marking contact lenses visual clarity
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CanagliflozinPhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+34%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →